Navigation Links
Prof. Michel Klein Becomes Chief Scientific Officer at AMVAC
Date:10/11/2007

ZUG, Switzerland, October 11 /PRNewswire/ -- The young Swiss biotech enterprise AMVAC AG has gained reinforcement from Prof. Michel Klein, one of the world's most renowned vaccine specialists. Prof. Klein, who was formerly Vice President of Science & Technology of the Aventis-Pasteur Group, will immediately assume directorship of the scientific sector of vaccine development at AMVAC AG. This distinguished vaccinologist has access to an outstanding network across one of the greatest growth markets and will make a critical contribution in AMVAC AG's product research and development. Along with the vaccine against bacterial vaginosis already approved in Hungary, Klein is focusing on the further development of a vaccine against prostate enlargement, for which the performance of a clinical phase III study has been approved. In addition, AMVAC AG is preparing new projects for indications unnamed until now. Official statements on more new projects in the pharmaceutical industry will be released in the coming weeks.

Melinda Karpati, CEO of AMVAC, AG says, "Being able to win Prof. Michel Klein is a great success for us and affirms not only AMVAC AG's executive? direction, but also the continued recognition that we have come to know on the part of experienced experts in the field of vaccine development. His global network and the tremendous experience that Prof. Michel Klein brings to AMVAC AG will help us develop novel prophylactic and immunotherapeutic products in the pharmaceutical industry. Our new CSO's 40-year career has included numerous scientific publications, distinctions and groundbreaking vaccine developments. He has developed the five-component acellular pertussis vaccine currently on the market, brought vaccines against PIV-3, RSV and flu to phase I/II trials, launched the cancer vaccine program of Aventis-Pasteur and performed more than 40 trials with several prototypes of prophylactic and therapeutic HIV vaccines in collaboration with the NIH, WRAIR, Eurovac and the ANRS. He is the author of more than 350 patents in the fields of vaccinology, immunology, infectious diseases and biotechnology.

About AMVAC AG

AMVAC AG is a young biopharmaceutical company based in Switzerland that is concentrating in the high-yield pharmaceutical industry on an especially high-growth market segment. An average annual growth rate of 13% is forecast until 2010 for the vaccines market, compared with 6% for pharmaceuticals in general. AMVAC products are further characterized by meeting unfulfilled therapy requirements in the fields of urology and gynecology. AMVAC has to date licensed and further developed two advanced immunotherapeutic drugs with gold standard potential. Further products are in the planning stage.

Contact:

AMVAC AG

Ariane Meynert

Metallstrasse 4

6300 Zug

Switzerland

Phone: +41-41-725-32-30

Fax: +41-41-725-32-33

Mobile: +41-79-793-34-19 / +49-172-775-92-12

E-Mail:meynert@amvac.ch


'/>"/>
SOURCE AMVAG AG
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Safe Internet requires total network security, prof. says
2. Daugherty becomes CTO of Great Lakes BioFuels
3. DataPod becomes BeInSync so you can, too
4. Boston equity firm becomes majority owner of Cedarburg-based Mortgagebot
5. Historic observatory becomes hot property on Lake Geneva
6. State technology chief endorses IT audit recommendations
7. Fusion 2007: CA chief says IT complexity raises risk
8. Web-Based Learning Developed under new Chief Education Officer
9. UW-Madisons Beebe wins scientific award
10. Researchers say scientific reporting needs more perspective, less hype
11. Wisconsin stands at the center of scientific efforts to avert flu epidemics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... 23, 2016 On Wednesday, June 22, ... down 0.22%; the Dow Jones Industrial Average edged 0.27% lower ... 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the following ... Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... BIND ). Learn more about these stocks by accessing ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... a new line of intelligent tools designed, tuned and optimized exclusively for Okuma ... 12–17 in Chicago. The result of a collaboration among several companies with expertise ...
(Date:6/22/2016)... DIEGO , June 22, 2016 ... that will allow them to produce up to ... from one lot within one week. These high-quality, ... time laboriously preparing cells and spend more time ... possible through a proprietary, high-volume manufacturing process that ...
Breaking Biology Technology:
(Date:5/3/2016)... May 3, 2016  Neurotechnology, a provider of ... MegaMatcher Automated Biometric Identification System (ABIS) , a ... projects. MegaMatcher ABIS can process multiple complex biometric ... combination of fingerprint, face or iris biometrics. It ... and MegaMatcher Accelerator , which have ...
(Date:4/26/2016)... 2016 Research and Markets has ... Market 2016-2020"  report to their offering.  , ,     ... The analysts forecast the global multimodal biometrics market ... the period 2016-2020.  Multimodal biometrics is ... as the healthcare, BFSI, transportation, automotive, and government ...
(Date:4/14/2016)... Israel , April 14, 2016 ... Authentication and Malware Detection, today announced the appointment of ... assumed the new role. Goldwerger,s leadership appointment ... on the heels of the deployment of its platform ... BioCatch,s behavioral biometric technology, which discerns unique cognitive and ...
Breaking Biology News(10 mins):